Intercept Pharmaceuticals Inc., is a clinical stage biopharmaceutical company developing therapeutics for the treatment of chronic fibrotic and metabolic diseases.
Current News
  • August 9, 2011 - Intercept Pharmaceuticals and Servier Announce Agreement for Intercept's TGR5 Research Program in Type 2 Diabetes...More »


  • March 31, 2011 - Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis...More »


  • March 30, 2011 - Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease...More »


  • March 29, 2011 - Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals Obeticholic Acid (INT-747) in NASH...More »


Upcoming Events
  • April 20, 2012 - Intercept Pharmaceuticals, Inc.'s collaborator, Gideon Hirschfield, MD, PhD, Clinicial Investigator at the Toronto Western Hospital Liver Centre, will present: "Long-Term (LT) Therapy of a Farnesoid X Receptor (FXR) Agonist Obeticholic Acid (OCA) Maintains Biochemical Response in Primary Biliary Cirrhosis (PBC)" at the European Society for the Study of the Liver (EASL) annual conference in Barcelona, Spain, on Friday, April 20, 2012.


  • April 20, 2012 - Intercept Pharmaceuticals, Inc.'s collaborator, Hanns-Ulrich Marschall, MD, PhD, Professor of Clinical Hepatology, Sahlgrenska Academy, University of Gothenburg, will present: "The Farnesoid X Receptor (FXR) Agonist Obeticholic Acid (OCA) Increases Plasma FGF-19 Concentrations and Decreases Bile Acid Synthesis in Primary Biliary Cirrhosis (PBC)" at the EASL annual conference in Barcelona, Spain, on Friday, April 20, 2012.